A Meta-Analysis of Randomized Controlled Trials on Antiplatelet Agents Versus Placebo/Control for Treating XXXX .

@entity1 @entity64 @entity3657 @entity548 @entity117 @entity432 @entity583 @entity204 @entity65
Effect of @entity117 (antiplatelet agents) in @entity1 with @entity3657 ( @entity3657 ) was still controversial. Varying studies reported varying results. Therefore, we did this meta-analysis to investigate if @entity117 could reduce cardiovascular events in @entity1 with @entity3657 .A comprehensive literature search (PubMed, CCTR, Embase, Web of Science, CNKI, CBM-disc, and relevant websites) was conducted from 1990 to September 2014. The key search terms (" @entity117 ," " @entity3657 ," "peripheral @entity432 ," and "claudication") produced 9 high-quality randomized controlled trials (RCTs) of @entity117 versus placebo/control. Mantel-Haenszel random-effects model was used to analysis of the 9 RCTs. The primary outcome was the cardiovascular events.Nine RCTs, composed of 9526 @entity1 (4786 @entity117 -treated and 4740 placebo or control-treated @entity1 ), were meta-analyzed. The results indicated that compared to placebo/control, @entity117 could not significantly reduce the cardiovascular events (OR=0.81, 95% CI=0.56-1.15). Moreover, @entity117 could not produce better effect on prevention of nonfatal @entity583 (OR=0.98, 95% CI=0.52-1.84), @entity64 (OR=0.89, 95% CI=0.69-1.14), @entity65 (OR=0.97, 95% CI=0.68-1.38), any @entity204 (OR=1.05, 95% CI=0.85-1.30), and major @entity548 (OR=1.16, 95% CI=0.82-1.65) than placebo/control. But @entity117 , as monotherapy therapy, did significantly reduce the risk of @entity64 (OR=0.42, 95% CI=0.21-0.84). @entity117 , as monotherapy or combination therapy, did not result in a significant decrease in the cardiovascular events. But @entity117 , as monotherapy therapy, did significantly reduce the risk of @entity64 . Our conclusion might help clinicians in clinical treating @entity3657 . Future studies are needed to draw firm conclusions about the clinical benefit and risks of @entity117 and other antiplatelet agents.
